Novel 5-Lipoxygenase Inhibitor (SC-41661) Reduces Human Ovarian Cancer Cell Invasion and Ascitic Tumor Growth

  • R. Fridman
  • T. Kanemoto
  • G. R. Martin
  • T. Hamilton
  • R. A. Partis
  • R. A. Mueller
Part of the Developments in Oncology book series (DION, volume 67)


Ovarian cancer, the fourth leading cause of cancer-related deaths in American women, accounts for nearly 15,000 deaths annually (1). The tumor arises from the epithelial cells covering the surface of the ovary. These cells proliferate, escape from the primary tumor, and spread into the peritoneal cavity where multiple secondary tumors form that are difficult to remove or to treat. The obstruction of peritoneal lymphatics by the tumor cells further results in the development of ascites. The formation of ascites can then further facilitate the spread of malignant cells to other sites within the peritoneal cavity. The most common form of treatment for ovarian cancer involves the surgical excision of intraperitoneal tumors, followed by chemotherapy. Small tumor masses cannot be easily removed. Furthermore, ovarian cancer is clinically noted for the rapid development of primary drug resistance and a broad cross resistance to conventional chemotherapy which makes this tumor particularly difficult to treat.


Ovarian Cancer Ovarian Carcinoma Cell Line Human Ovarian Carcinoma Cell Modify Boyden Chamber Intraperitoneal Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Richardson, G.S., Scully, R.E., Nikrui, N., and Nelson, J.H. N. Eng. J. Med. 312:415–424, 1985.CrossRefGoogle Scholar
  2. 2.
    Powles, T.J., Bockman, R.S., Honn, K.V., and Ramwell, P.W. (eds.) Prostaglandins and Cancer, New York, Alan R. Liss, Inc., 1984.Google Scholar
  3. 3.
    Young, M.R., Young, M.E., and Wepsic, H.T. Cancer Res. 47:3679–3683, 1987.PubMedGoogle Scholar
  4. 4.
    Kort, W.J. Hulsman, L.O.M., van Schalkwijk, W.P., Wejima, I.M., Zondervan, P.E., and Westbroek, D.L. J. Nat’l. Cancer Inst. 76:711–720, 1986.Google Scholar
  5. 5.
    Reich, R., and Martin, G.R. Cancer Res., submitted, 1989.Google Scholar
  6. 6.
    Mueller, R.A., and Partis, R.A., US Patent 4,663,333, 1988.Google Scholar
  7. 7.
    Nakao, A., Yang, O-C, Jung, G., Partis, R.A., and Mueller, R.A., in preparation.Google Scholar
  8. 8.
    Hamilton, T.C., Young, R.C., Laurie, K.G., Bephens, B.C., McKoy, W.M., Grotzinger, K.R., and Ozols, R.F. Cancer Res. 44:5286–5290, 1984.PubMedGoogle Scholar
  9. 9.
    Kleinman, H.K., McGarvey, M.L., Hassell, J.R., Star, V.L., Cannon, F.B., Laurie, G.W., and Martin, G.R. Biochem. 25:312–318, 1986.CrossRefGoogle Scholar
  10. 10.
    Albini, A., Iwamoto, Y., Kleinman, H.K., Martin, G.R., Aaronson, S.A., Kozlowski, J.M., and McEwan, R.N. Cancer Res., 47:3239–3245, 1989.Google Scholar
  11. 11.
    Kramer, R.H., Bensch, K.G., and Wong, J. Cancer Res. 46:1980–1989, 1986.PubMedGoogle Scholar
  12. 12.
    Fridman, R. Lacal, J.C., Reich, R., Bonfil, R.D., and Ahn, C. J. Cell. Physiol., in press, 1989.Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • R. Fridman
    • 1
  • T. Kanemoto
    • 1
  • G. R. Martin
    • 2
  • T. Hamilton
    • 3
  • R. A. Partis
    • 4
  • R. A. Mueller
    • 4
  1. 1.Lab. Devel. Biol. and AnomaliesNIDR, NIHBethesdaUSA
  2. 2.Gerontology Research Ctr.NIA, NIH, BaltimoreUSA
  3. 3.Med. OncologyFox Chase Cancer Ctr.PhiladelphiaUSA
  4. 4.Molec. and Cell. Biol. Dept.G.D. Searle & CoSkokieUSA

Personalised recommendations